ABBV · News · 20260923N

Regulatory Approval Milestones

AbbVie Inc. · 2026-09-23 · Importance 31 · Surprise 42

The European Union approved Rinvoq (upadacitinib) for active polyarticular juvenile idiopathic arthritis in patients aged two and older. The approval is Rinvoq’s 11th EU indication and expands AbbVie’s immunology portfolio as the company seeks to offset Humira-related erosion. The pediatric label expansion supports the company’s longer-term growth strategy in immunology, although the reports did not disclose a specific financial contribution or launch timeframe.